Recently, Gauthier et al. introduced trifunctional natural killer cell engagers (NKCEs) co-engaging not only CD16 but also NKp46, another activating NK cell receptor, and a tumor-specific antigen, yielding impressive outcomes in in vitro and in vivo experiments while exhibiting an improved safety profile when compared to BiTEs (19). The gene discussed is FCGR3A; the disease is neoplasm.